MedTrace Logo

A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

NCT01488838 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2016-02-25

No results posted yet for this study

Summary

A Randomized Phase II study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation alone in Resected High-Risk Malignant Salivary Gland Tumors

Conditions

  • Malignant Salivary Gland Tumors

Interventions

DRUG

Cisplatin: 40 mg/m2 weekly during radiation

Cisplatin: 40 mg/m2 weekly during radiation for 7 doses

RADIATION

Radiation: 60-66 Gy in 2 Gy daily fractions

Radiation: 60-66 Gy in 2 Gy daily fractions

Sponsors & Collaborators

  • Radiation Therapy Oncology Group

    collaborator NETWORK

  • King Faisal Specialist Hospital & Research Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01488838 on ClinicalTrials.gov